119th Congress · introduced in the House · Jan 28, 2025
Second Chance for Moms Act
Official title from Congress.gov
Latest action (Jan 28, 2025): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Jan 28, 2025)
Second Chance for Moms Act of 2025
This bill requires labeling of the drug mifepristone to include certain information about the hormone progesterone and establishes a related telephone hotline. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Abortion · Consumer affairs · Prescription drugs · Sex and reproductive health · Telephone and wireless communication · Women's health
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
3 citations.
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$420,000
Spent on own lobbying
…nuary 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes; H.R. 795 Pregnancy Is Not an Illness Act; H.R. 796 Second Chance for Moms Act; H.R. 1349 Womens Protection in Telehealth Act; H.R. 1525 Protecting Life from Chemical Abortions Act; H.R. 627 Ensuring Accurate &…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Family issues/Abortion/Adoption
$420,000
Spent on own lobbying
…nuary 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes; H.R. 795 Pregnancy Is Not an Illness Act; H.R. 796 Second Chance for Moms Act; H.R. 1349 Womens Protection in Telehealth Act; H.R. 1525 Protecting Life from Chemical Abortions Act; H.R. 627 Ensuring Accurate &…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Pharmacy
$420,000
Spent on own lobbying
…nuary 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes; H.R. 795 Pregnancy Is Not an Illness Act; H.R. 796 Second Chance for Moms Act; H.R. 1349 Womens Protection in Telehealth Act; H.R. 1525 Protecting Life from Chemical Abortions Act; H.R. 627 Ensuring Accurate &…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing